Who are CAR-T-19 cell injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, BLINATUMOMAB, Blincyto, SCT800 and Daratumumab, IL-7/IL-15 pre-treated CD19 cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/car-t-19-cell-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CAR-T-19 cell injection — Competitive Intelligence Brief

CAR-T-19 cell injection (CAR-T-19 cell injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 2 CAR-T cell therapy CD19 Oncology Biologic Live · refreshed every 30 min

Target snapshot

CAR-T-19 cell injection (CAR-T-19 cell injection) — Beijing Yongtai Ruike Biotechnology Company Ltd. CAR-T-19 is a chimeric antigen receptor T-cell therapy engineered to recognize and kill CD19-expressing B-cell malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAR-T-19 cell injection TARGET	CAR-T-19 cell injection	Beijing Yongtai Ruike Biotechnology Company Ltd	phase 2	CAR-T cell therapy	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
SCT800 and Daratumumab	SCT800 and Daratumumab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Bispecific T-cell engager (SCT800); CD38-targeting monoclonal antibody (Daratumumab)	CD19 and CD3 (SCT800); CD38 (Daratumumab)
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
Guangzhou Women and Children's Medical Center · 2 drugs in this class
Sinocelltech Ltd. · 2 drugs in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
Celyad Oncology SA · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class
EdiGene Inc. · 1 drug in this class
Hrain Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CAR-T-19 cell injection — Competitive Intelligence Brief. https://druglandscape.com/ci/car-t-19-cell-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab